SCHEMBL2120108

SCHEMBL2120108

CCn1ccc(S(=O)(=O)Nc2cc(C)cc(-c3ccc(OC)cn3)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
MAPT P10636 4/20 0.39
GAA P10253 1/20 0.39
XBP1 P17861 1/20 0.39
PIK3CB P42338 1/20 0.39
ALDH1A1 P00352 4/20 0.39
SYK P43405 2/20 0.39
PKM P14618 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HTT P42858 2/20 0.38
POLB P06746 2/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA3 P34903 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
AURKA O14965 1/20 0.37
PLAU P00749 1/20 0.37
NPY5R Q15761 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2116904 0.87 LMNA (0.41) LMNAMAPTGAAPIK3CBALDH1A1
SCHEMBL2119833 0.83 MAPT (0.52) LMNAMAPTALDH1A1PKMNPSR1
SCHEMBL2118607 0.83 FFAR4 (0.54) LMNAMAPTGAAPIK3CBALDH1A1
SCHEMBL2118551 0.82 PIK3CB (0.50) LMNAMAPTGAAPIK3CBALDH1A1
SCHEMBL2118102 0.78 PIK3CB (0.41) LMNAMAPTPIK3CBALDH1A1SYK
SCHEMBL2118552 0.75 FFAR4 (0.51) LMNAMAPTPIK3CBALDH1A1SYK
SCHEMBL2119384 0.75 MAPT (0.36) LMNAMAPTGAAXBP1ALDH1A1
SCHEMBL2119912 0.73 GAA (0.47) LMNAMAPTGAAXBP1PKM
SCHEMBL2120549 0.73 STAT3 (0.48) LMNAMAPTGAAPIK3CBALDH1A1
SCHEMBL2119228 0.70 MAPT (0.54) LMNAMAPTALDH1A1PKMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 LMNA 2810/4885MAPT 4747/4885GAA 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.